Roflumilast for the treatment of chronic obstructive pulmonary disease

Expert Review of Respiratory Medicine
Klaus F Rabe

Abstract

Roflumilast is a new phosphodiesterase 4 inhibitor that has recently completed Phase III trials for the treatment of chronic obstructive pulmonary disease (COPD). Preclinical studies have shown that roflumilast targets inflammatory processes in COPD, with beneficial effects on tobacco-induced lung inflammation, lung fibrosis and remodeling, mucociliary malfunction and oxidative stress. Two recent, 1-year Phase III trials in COPD have shown that roflumilast reduces exacerbations and improves lung function in patients with COPD who have symptoms of chronic bronchitis and a history of exacerbations. Two other 6-month Phase III trials have demonstrated the beneficial effects of roflumilast in patients already receiving treatment with the long-acting β-agonist salmeterol or the long-acting muscarinic antagonist tiotropium. This article reviews the pharmacology, pharmacokinetics and preclinical pharmacology of roflumilast, the clinical studies supporting its use in COPD and its side-effect profile.

References

Jan 5, 2000·Progress in Drug Research. Fortschritte Der Arzneimittelforschung. Progrès Des Recherches Pharmaceutiques·M S Barnette
Jun 10, 2000·Chest·W MacNee
Apr 3, 2001·American Journal of Respiratory and Critical Care Medicine·C SinderbyJ Beck
Aug 14, 2001·American Journal of Respiratory and Critical Care Medicine·R E KannerUNKNOWN Lung Health Study Research Group
May 10, 2002·The European Respiratory Journal·S SantosJ A Barberà
Nov 30, 2002·Trends in Pharmacological Sciences·Mark A Giembycz
Feb 14, 2003·Lancet·Peter CalverleyUNKNOWN TRial of Inhaled STeroids ANd long-acting beta2 agonists study group
May 24, 2003·Cell and Tissue Research·Katherine B Pryzwansky, Victoria J Madden
Oct 30, 2003·The European Respiratory Journal·P J BarnesR A Pauwels
Jun 25, 2004·The New England Journal of Medicine·James C HoggPeter D Paré
May 10, 2005·Respiratory Medicine·A G N Agusti
Jun 3, 2005·The European Respiratory Journal·P J Barnes, R A Stockley
Jun 16, 2005·Respirology : Official Journal of the Asian Pacific Society of Respirology·Shunichi FukuharaJohn W Peabody
Jun 18, 2005·American Journal of Respiratory and Critical Care Medicine·Piero A MartoranaGiuseppe Lungarella
May 17, 2006·Clinical and Experimental Pharmacology & Physiology·Travis J NickelsDavid F Wilson
Sep 20, 2006·Expert Opinion on Therapeutic Targets·Stephan E Lehnart, Andrew R Marks
Sep 20, 2006·British Journal of Clinical Pharmacology·Nassr NassrRobert Hermann
Dec 2, 2006·COPD·Russell P BowlerJames D Crapo
Feb 23, 2007·The New England Journal of Medicine·Peter M A CalverleyUNKNOWN TORCH investigators
Apr 28, 2007·American Journal of Respiratory and Critical Care Medicine·Peter M A CalverleyLeonardo M Fabbri
Jun 29, 2007·Clinical Pharmacokinetics·Oliver von RichterRobert Hermann
May 31, 2008·American Journal of Respiratory and Critical Care Medicine·Bartolomé R CelliPeter M A Calverley
Sep 10, 2008·Chest·Stephen I Rennard, Jørgen Vestbo
Oct 7, 2008·The New England Journal of Medicine·Donald P TashkinUNKNOWN UPLIFT Study Investigators
Nov 4, 2008·The European Respiratory Journal·A ChaouatE Weitzenblum
Nov 20, 2008·Chest·Pierre-Régis BurgelUNKNOWN Initiatives Bronchopneumopathie Chronique Obstructive (BPCO) Scientific Committee
Jan 1, 2008·Drugs·Stephen RennardFrank Barnhart
Jan 22, 2009·British Journal of Pharmacology·J CortijoE J Morcillo

❮ Previous
Next ❯

Citations

Jun 21, 2011·American Journal of Respiratory Cell and Molecular Biology·Andrew ChurgJoanne L Wright
Dec 14, 2011·Revue des maladies respiratoires·P DevillierN Roche
Mar 17, 2012·The Consultant Pharmacist : the Journal of the American Society of Consultant Pharmacists·Maisha L Kelly Freeman
Feb 13, 2014·Basic & Clinical Pharmacology & Toxicology·Katharine H Abbott-Banner, Clive P Page
Jan 22, 2017·Physiological Reports·Ezigbobiara N UmejiegoChung-Lin Chou
Jun 5, 2013·Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia·Vladimir KoblizekUNKNOWN Czech Pneumological and Phthisiological Society
Jan 19, 2020·Cellular Signalling·Stefan HadzicDjuro Kosanovic

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.